Evidence map›Paper›PMID 36388247›Full record

ArticleClinical and translational radiation oncology2023

10-Year oncological outcome report after second conservative treatment for ipsilateral breast tumor event.

Jean-Michel Hannoun-Levi, Jocelyn Gal, Renaud Schiappa, Marie-Eve Chand

Abstract read
In one paragraph

Article in Clinical and translational radiation oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jean-Michel Hannoun-LeviDepartment of Radiation Oncology, Antoine Lacassagne Cancer Centre, University of Côte d'Azur, Nice, France.
Jocelyn GalDepartment of Epidemiology and Biostatistics, Antoine Lacassagne Cancer Centre, University of Cote d'Azur, Nice, France.
Renaud SchiappaDepartment of Epidemiology and Biostatistics, Antoine Lacassagne Cancer Centre, University of Cote d'Azur, Nice, France.
Marie-Eve ChandDepartment of Radiation Oncology, Antoine Lacassagne Cancer Centre, University of Côte d'Azur, Nice, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To analyze long-term oncological outcome after 2nd conservative treatment (2 Materials/methods: In this retrospective observational study (N°F20210402152843), patients with 2 Results: Between 09/2000 and 04/2022, 244 patients presented a 2 Conclusions: With long follow-up, 2

Indexed as

1stCT, first conservative treatment1stIBTE, first ipsilateral breast tumor event2ndCT, second conservative treatment2ndIBTE, second ipsilateral breast tumor event3rdIBTE-FS, third ipsilateral breast tumor event free survival3rdIBTE, third ipsilateral breast tumor event95%CI, 95% confidence intervalAPBI, accelerated and partial breast irradiationAPBrI, accelerated and partial breast re-irradiationBrachytherapyBreast cancerCTCAE, Common Toxicity Criteria for Adverse EventsCTV, clinical target volumeDFS, disease-free survivalESMO, European Society for Medical OncologyGEC-ESTRO, Groupe Européen de Curiethérapie European Society for Radiotherapy and OncologyHDR, high-dose rateLDR, low-dose rateLocal recurrenceMastectomyMDFS, metastatic disease-free survivalMFU, median follow-upMIB, multi-catheter interstitial brachytherapyOS, overall survivalRRFS, regional recurrence free survivalSalvage treatmentSM, salvage mastectomySS, specific survival

Identifiers

PMID36388247
PMCPMC9646647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.